rhG-CSF group

DRUG2 trials

Sponsors

Xiamen Amoytop Biotech Co., Ltd., CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Conditions

LeukemiaLymphomaMycoses

Phase 4

Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT

CompletedNCT01232504

Xiamen Amoytop Biotech Co., Ltd.Mycoses

Start: 2009-09-30End: 2013-06-30Updated: 2014-11-04

Unknown Phase

Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Leukemia, Lymphoma

Start: 2020-08-01End: 2021-12-01Target: 139Updated: 2020-08-04